Recce Pharmaceuticals

Recce Pharmaceuticals Equity

The The Equity of Recce Pharmaceuticals (RCE.AX) as of Oct 22, 2026 is -16.72 M AUD. In the previous year, The Equity was -3.05 M AUD — a change of 447.93% (lower).

Equity

-16.72 MAUD

YoY

447.93%

Last updated:

In 2026, Recce Pharmaceuticals's equity was -16.72 M AUD, a 447.93% increase from the -3.05 M AUD equity in the previous year.

The Recce Pharmaceuticals Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
-405,604.00 AUD
Jan 1, 2020
2.31 M AUD
Jan 1, 2021
20.50 M AUD
Jan 1, 2022
10.06 M AUD
Jan 1, 2023
-2.59 M AUD
Jan 1, 2024
-9.52 M AUD
Jan 1, 2025
-3.05 M AUD
Jan 1, 2026
-16.72 M AUD
The Recce Pharmaceuticals Equity history
YEAREquityYoY
-16.72 MAUD+447.93%
-3.05 MAUD-67.95%
-9.52 MAUD+267.88%
-2.59 MAUD-125.73%
10.06 MAUD-50.93%
20.50 MAUD+786.62%
2.31 MAUD-670.16%
-405,604.00AUD-158.37%
694,915.00AUD+17.75%
590,144.00AUD-83.21%
3.51 MAUD-25.46%
4.71 MAUD-8,489.74%
-56,189.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Recce Pharmaceuticals's Equity

Recce Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Recce Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Recce Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Recce Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Recce Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Recce Pharmaceuticals stock

The Equity of Recce Pharmaceuticals is -16.72 M AUD in 2026.

The Equity of Recce Pharmaceuticals changed from -3.05 M AUD to -16.72 M AUD, representing a 447.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Recce Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Recce Pharmaceuticals

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Recce Pharmaceuticals